Investigational drug · Phase 2
BRX011
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Geographic Atrophy.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BRX011"
First trial start
2026
Sep 29, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BRX011", any sponsor or status.
Conditions studied
As listed on its trial records.
- Geographic Atrophy
Approved drugs for the same conditions: Geographic atrophy
Largest trials
Live from ClinicalTrials.gov: studies naming "BRX011" as an intervention, largest first.
- A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular DegenerationPivotal-lookingRecruiting
Biojiva LLCIndustry
NCT07029945 · 152 participants (planned) · Start Sep 29, 2026 · Primary completion Apr 2029
Drug: BRX011; Placebo · For: Geographic Atrophy
Sites: Gilbert, Arizona; Phoenix, Arizona; Hattiesburg, Mississippi · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Geographic Atrophy
- TinlarebantLBS-008Phase 33 trials
Belite Bio, Inc · Stargardt Disease 1, STGD1, Geographic Atrophy
- JNJ-81201887AAVCAGsCD59Phase 32 trials
Johnson & Johnson (Janssen) · Geographic Atrophy, Macular Degeneration
- VonaprumentANX007Phase 32 trials
Annexon, Inc. · Geographic Atrophy
- OpRegenPhase 22 trials
Roche (Genentech) · Age-Related Macular Degeneration, Geographic Atrophy
- STL303Phase 22 trials
Sitala Bio LTD · IgAN, Geographic Atrophy
- ABBV-6628Phase 21 trial
AbbVie · Geographic Atrophy, Age-Related Macular Degeneration
- BI 1584862Phase 21 trial
Boehringer Ingelheim · Geographic Atrophy
- BI 771716Phase 21 trial
Boehringer Ingelheim · Macular Degeneration, Age-related, Geographic Atrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.